NASDAQ · RLAY
Relay Therapeutics, Inc.
Healthcare · Biotechnology
$18.20▲ 2.90% ($0.51)today
As of 3:07 PM ET
Market cap
$3.99B
P/E
Valuation
Revenue & margin DCF
Verdict: expensive. Price above all scenarios.
The price needs 87.2% revenue growth a year for 10 years. Our scenarios assume 8.4–14.6%.
That's 1.7× its past 4-year pace.
Value per share
Base case
$4.54
Price used $18.20 is 4.0× this
USD · TTM ending Jun 30, 2026 · Price Sep 29, 7:07 PM UTC
Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.
Revenue each value needs
Revenue today $10.4M. The price needs $5.5B by 2036. Base case: $31.4M. At its recent pace: $599M. Bear to Bull: $23.3M to $40.6M.
Revenue today $10.4M. The price needs $5.5B by 2036. Base case: $31.4M. At its recent pace: $599M. Bear to Bull: $23.3M to $40.6M.
Revenue in 2036
today $10.4M
+$5.4Bmore than the Base case · 174.4×
Value per share · Base case
$4.54
Price $18.20
4.0× this
- 10-yr revenue CAGR
- 11.7%
- Ending operating margin
- 0.0%
- Discount rate
- 14.6%
Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.
USD · TTM ending Jun 30, 2026 · Price Sep 29, 7:07 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
What changed
The stock rose 250.73% over the last year. Revenue grew 23.86% over the trailing twelve months. Operating margin moved from -4,105.6% to -2,999.38%. Free cash flow grew 19.02% over the trailing twelve months.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum. The operating data is doing enough work that the move does not need an overvaluation story to explain it.
What would invalidate this read
Operating margin is at -2,999.38%. Revenue grew 23.86% — this thesis depends on that trajectory holding. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Return analysis
Company profile
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials.
Market multiples
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
15
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 5, 2026
Q3 FY26 · EPS est -$0.40 · Revenue est $1.62M
View
Institutional Sentiment
Relay Therapeutics, Inc. · RLAY
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.